Jump Financial LLC Makes New Investment in Disc Medicine, Inc. (NASDAQ:IRON)

Jump Financial LLC bought a new position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 11,507 shares of the company's stock, valued at approximately $730,000.

Other hedge funds also recently bought and sold shares of the company. Sterling Capital Management LLC boosted its holdings in Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after buying an additional 503 shares during the period. KLP Kapitalforvaltning AS bought a new position in Disc Medicine in the 4th quarter worth $235,000. Teacher Retirement System of Texas boosted its holdings in Disc Medicine by 8.9% in the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after buying an additional 396 shares during the period. Virtu Financial LLC bought a new position in Disc Medicine in the 4th quarter worth $309,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Disc Medicine by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock worth $400,000 after purchasing an additional 593 shares in the last quarter. Institutional investors own 83.70% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on IRON shares. Stifel Nicolaus boosted their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday, January 24th. Cantor Fitzgerald boosted their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. TD Cowen started coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a "buy" rating on the stock. Morgan Stanley reiterated an "overweight" rating and issued a $85.00 price target on shares of Disc Medicine in a research note on Friday, March 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $93.80.

Insider Transactions at Disc Medicine

In other news, COO Jonathan Yen-Wen Yu sold 1,610 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $87,873.80. Following the sale, the chief operating officer now directly owns 40,555 shares in the company, valued at approximately $2,213,491.90. This represents a 3.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Jean M. Franchi sold 3,136 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $171,162.88. Following the completion of the sale, the chief financial officer now owns 69,530 shares in the company, valued at approximately $3,794,947.40. The trade was a 4.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 361,690 shares of company stock worth $19,648,094. 4.24% of the stock is currently owned by company insiders.

Disc Medicine Stock Performance

IRON stock traded up $0.74 during midday trading on Monday, reaching $46.16. 302,472 shares of the company traded hands, compared to its average volume of 345,257. Disc Medicine, Inc. has a 52-week low of $27.39 and a 52-week high of $68.73. The business has a 50 day moving average of $48.38 and a 200-day moving average of $55.12. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -11.60 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.06) by $0.08. Research analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.